Shiraz Bhurwani, Mohammad Mahdi
Snyder, Kenneth V.
Waqas, Muhammad
Mokin, Maxim
Rava, Ryan A.
Podgorsak, Alexander R.
Chin, Felix
Davies, Jason M.
Levy, Elad I.
Siddiqui, Adnan H.
Ionita, Ciprian N. http://orcid.org/0000-0001-7049-0592
Funding for this research was provided by:
James H. Cummings Foundation
The University at Buffalo Clinical and Translational Science Institute
Article History
Received: 3 September 2020
Accepted: 3 November 2020
First Online: 7 January 2021
Compliance with ethical standards
:
: Maxim Mokin—Grants: Principal investigator NIH R21NS109575. Consultant: Medtronic, Cerenovus. Stock options: Serenity Medical, Synchron, Endostream, VICIS.Ciprian Ionita—Equipment grant from Canon Medical Systems, support from the Cummings Foundation, NIH R21 grant.Jason Davies—Research grant: National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR001413 to the University at Buffalo. Speakers’ bureau: Penumbra; Honoraria: Neurotrauma Science, LLC. Shareholder/ownership interests: RIST Neurovascular.Kenneth Snyder—Consulting and teaching for Canon Medical Systems Corporation, Penumbra Inc., Medtronic, and Jacobs Institute. Co-Founder: Neurovascular Diagnostics, Inc.Elad Levy—Shareholder/ownership interests: NeXtGen Biologics, RAPID Medical, Claret Medical, Cognition Medical, Imperative Care (formerly the Stroke Project), Rebound Therapeutics, StimMed, Three Rivers Medical. National Principal Investigator/Steering Committees: Medtronic (merged with Covidien Neurovascular) SWIFT Prime and SWIFT Direct Trials. Honoraria: Medtronic (training and lectures). Consultant: Claret Medical, GLG Consulting, Guidepoint Global, Imperative Care, Medtronic, Rebound, StimMed. Advisory Board: Stryker (AIS Clinical Advisory Board), NeXtGen Biologics, MEDX, Cognition Medical, Endostream Medical. Site Principal Investigator: CONFIDENCE study (MicroVention), STRATIS Study—Sub I (Medtronic).Adnan Siddiqui—Research grant: NIH/NINDS 1R01NS091075 as a co-investigator for “Virtual Intervention of Intracranial Aneurysms.” Financial interest/investor/stock options/ownership: Amnis Therapeutics, Apama Medical, Blink TBI Inc., Buffalo Technology Partners Inc., Cardinal Consultants, Cerebrotech Medical Systems, Inc., Cognition Medical, Endostream Medical Ltd., Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics Inc., Q’Apel Medical Inc., Rebound Therapeutics Corp., Rist Neurovascular Inc., Serenity Medical Inc., Silk Road Medical, StimMed, Synchron, Three Rivers Medical Inc., Viseon Spine Inc. Consultant/advisory board: Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc., Cerebrotech Medical Systems Inc., Cerenovus, Corindus Inc., Endostream Medical Ltd., Guidepoint Global Consulting, Imperative Care, Integra LifeSciences Corp., Medtronic, MicroVention, Northwest University–DSMB Chair for HEAT Trial, Penumbra, Q’Apel Medical Inc., Rapid Medical, Rebound Therapeutics Corp., Serenity Medical Inc., Silk Road Medical, StimMed, Stryker, Three Rivers Medical, Inc., VasSol, W.L. Gore & Associates. Principal investigator/steering comment of the following trials: Cerenovus LARGE and ARISE II; Medtronic SWIFT PRIME and SWIFT DIRECT; MicroVention FRED & CONFIDENCE; MUSC POSITIVE; and Penumbra 3D Separator, COMPASS, and INVEST.
: Institutional review board approval was obtained, and informed consent was waived for this Health Insurance Portability and Accountability Act–compliant retrospective study (IRB ID: STUDY00001529).
: This is a retrospective study; hence, no informed consent is needed.